We develop innovative treatments and improve the performance of proven molecules, leveraging our proprietary technology platforms. These enhanced products fulfill unmet medical needs, and are submitted to the FDA utilizing 505(b)(2) regulatory pathway.
Initially, the company derived its revenue from R&D services and on generic product milestones. Going forward, we envision the majority of our revenue will be coming from FDA- and National Medical Products Administration (NMPA)-approved product sales (generic product revenue for the near term and branded product revenue for the mid/long term).
The company also has 20+ pipeline products at various stages of development.